Research programme: Pediatric sarcoma therapeutics - Oncoheroes Biosciences
Latest Information Update: 20 Jul 2022
At a glance
- Originator Oncoheroes Biosciences
- Developer Oncoheroes Biosciences; Vall d-Hebron Research Institute
- Class Antineoplastics
- Mechanism of Action Hedgehog cell signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Sarcoma
Most Recent Events
- 19 Jul 2022 Research programme: Novel therapeutics for childhood sarcoma - Oncoheroes Biosciences is available for licensing as of 19 Jul 2022. https://oncoheroes.com/
- 18 Jul 2022 Early research in Sarcoma in Spain (unspecified route)
- 14 Jul 2022 Oncoheroes Biosciences and Vall d Hebron Research Institute collaborate for the discovery and development of innovative therapeutics for pediatric sarcomas